Efficacy and safety of JAK inhibitors in Behçet syndrome: systematic literature review.

In 30 seconds

This systematic literature review evaluated the efficacy and safety of JAK inhibitors in 92 patients with Behçet syndrome. The study found that JAK inhibitors achieved remission rates of 85.9% overall, with specific rates of 82.6% for gastrointestinal involvement and 90.9% for vascular involvement. Serious adverse events occurred in 5.4% of patients.

Key findings

• Remission rates for overall involvement were 85.9%, with 82.6% for gastrointestinal and 90.9% for vascular involvement.
• Serious adverse events were reported in 5.4% of patients.
• 90.6% of patients received JAK inhibitors in combination with other immunosuppressives or glucocorticoids.

Why it matters

The findings suggest that JAK inhibitors may be a viable treatment option for patients with refractory Behçet syndrome, particularly those with gastrointestinal and vascular manifestations, highlighting their potential role in managing this complex condition.